Twist Bioscience ( (TWST) ) has released its Q3 earnings. Here is a breakdown of the information Twist Bioscience presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Twist Bioscience Corporation is a mid-cap growth company specializing in synthetic biology, providing innovative DNA synthesis tools to various sectors including medicine, agriculture, and industrial chemicals. In its fiscal third quarter of 2025, Twist Bioscience reported a record revenue of $96.1 million, marking an 18% increase from the previous year, and achieved a gross margin of 53.4%, up from 43.3% in the same period last year. The company also noted significant growth in its Next-Generation Sequencing (NGS) and Biopharma segments, with revenues rising by 27% and 10%, respectively.
Key financial highlights include a net income of $20.4 million, a significant turnaround from a net loss of $85.6 million in the previous year. The company also improved its adjusted EBITDA to $(8.0) million from $(22.0) million year-over-year. Twist Bioscience expanded its customer base, shipping products to approximately 2,484 customers, and launched new products, including a humanized transgenic mouse model to enhance its antibody discovery services.
Looking ahead, Twist Bioscience has raised its full-year revenue guidance to between $374 million and $376 million, with an expected gross margin of 50.5% to 51%. The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, reflecting a positive outlook on its financial and operational strategies.